Loading resource…

Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands; Department of Cardiology, Amsterdam UMC, Vrije University (VU), Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands
The paper discusses the emerging alternative of early P2Y12 inhibitor monotherapy as a replacement for the traditional dual antiplatelet therapy following PCI in NSTE-ACS patients. It presents findings from a single-arm pilot study that included 75 patients, highlighting the safety and feasibility of this approach. Key outcomes include the absence of stent thrombosis and spontaneous myocardial infarction during follow-up, suggesting that this monotherapy could be a viable option for managing patients post-PCI.
No account needed